Advanced glycation end-product accumulation tied to sarcopaenia, dynapaenia
Accumulation of advanced glycation end-products (AGEs) may lead to sarcopaenia and dynapaenia in type 2 diabetes (T2D) patients by contributing to a decrease in muscle mass and strength, a recent study has shown.
A total of 166 T2D patients (mean age 63.2±12.3 years; 99 males), with an average body mass index (BMI) of 26.3±4.9 kg/m2 and glycated haemogolobin level of 7.1±1.1 percent, participated in the study. Skin autofluorescence, as a marker of AGEs, gait speed, knee extension strength, grip strength and limb skeletal muscle mass index were among the variables evaluated.
Of the participants, 13.9 percent had dynapaenia while 7.2 percent were diagnosed with sarcopaenia. The prevalence rates of low skeletal muscle mass index, grip strength, gait speed and knee extension strength were 11.5 percent, 22.3 percent, 6.6 percent and 59.0 percent, respectively.
Fully adjusted logistic regression models showed that skin autofluorescence was significantly and inversely associated with skeletal muscle mass index (odds ratio [OR], 6.38; 95 percent CI, 1.93–21.08), grip strength (OR, 3.55; 1.57–8.00) and knee extension strength (OR, 3.68; 1.87–7.23).
Moreover, skin autofluorescence was also significantly correlated with the prevalence of both sarcopaenia (OR, 7.73; 2.13–28.02) and dynapaenia (OR, 3.03; 1.07–8.54), such that the elevation of skin AF was an independent risk factor for both conditions.
Important limitations of the current study include its cross-sectional design, lack of information about participants’ diet and other pertinent laboratory data, and the small sample size, said researchers. Further studies are thus required to verify the relationships obtained in the present report.